Experience with the Use of Thio/Mel Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Autor: Tiranova Sa, EV Karyagina, Gritsaev Sv, ZhV Chubukina, Irina Martynkevich, SS Bessmeltsev, II Kostroma, Transfusiology, ya Sovetskaya str., Saint Petersburg, Russian Federation, AA Zhernyakova, AV Chechetkin, IM Zapreeva
Jazyk: ruština
Rok vydání: 2019
Předmět:
Zdroj: Kliničeskaâ onkogematologiâ, Vol 12, Iss 3, Pp 282-288 (2019)
ISSN: 2500-2139
1997-6933
Popis: Background. In multiple myeloma (MM) treatment a single autologous hematopoietic stem cell transplantation (auto-HSCT) is preceded by conditioning regimens aimed at intensifying cytoreductive effect. In the course of ongoing search for combined conditioning regimens an attractive option proved to be thiotepa/melphalan combination. Aim. Data analysis of a pilot study of the efficacy of conditioning regimens including administration of two alkylating agents (thiotepa and melphalan) with subsequent auto-HSCT. Materials & Methods. 9 patients received 10 auto-HSCTs with conditioning regimen including administration of 250 mg/m2 of thiotepa on Day -5 and 140 mg/m2 of melphalan on Day -2. After auto-HSCT pegylated filgrastim was administered in 8 patients. Engraftment period was calculated on the basis of absolute neutrophil count ≥ 0,5 x 109/L and thrombocyte level ≥ 20 x 109/L. Regimen toxicity was assessed according to CTCAE v5.0. Survival rates were estimated by Kaplan-Meier curves. Results. The use of thiotepa did not require administration of any additional drugs. The incidence of mucositis and enteropathy of grade 1-2 was 100 % and 70 %, respectively. Pyrexia was reported in 7 auto-HSCTs. Pneumonia occurred in 1 patient. The infusion of 1-3 doses of platelet concentrate (median of 2 doses) was required in all patients except for one. Donor erythrocytes were transfused to 3 patients. Engraftment was reported in all patients within the period of 10-14 days. Median hospitalization duration from Day 0 to hospital discharge was 16 patient-days. After auto-HSCT the quality of response improved in 6 out of 9 patients. MM progression was reported in one patient with complex karyotype. Further follow-up showed progression in 2 patients. By December 2018 median follow-up of 9 patients from the date of auto-HSCT was 9 months (range 3-20 months), me dian progression-free survival was 17 months, median overall survival was not reached. Conclusion. Acceptable toxicity, improvement of response quality, and maintenance of it for up to 20 months allow to consider combined conditioning regimen Thio/Mel to be a possible alternative to the standard Mel200 regimen.
Databáze: OpenAIRE
Externí odkaz: